| Literature DB >> 21382639 |
Francesca Buchi1, Roberta Pastorelli, Germano Ferrari, Elena Spinelli, Antonella Gozzini, Francesca Sassolini, Alberto Bosi, Donatella Tombaccini, Valeria Santini.
Abstract
Chronic myeloid leukaemia has a specific therapy: BCR/ABL inhibitor imatinib. Resistance due to BCR/ABL dependent and independent mechanisms is partially reversible by histone deacetylase inhibitors. We analysed by 2D-electrophoresis and anti-pan-acetylated and anti-phosphotyrosine immunoblots, followed by spot-matching and MALDI-TOF mass spectrometry, which proteome modifications would parallel restoration of sensitivity to imatinib by valproic acid (VPA). VPA plus imatinib significantly increased acetylation of HSP90 and hnRNP L and decreased phosphorylation of HSPs and hnRNPs in imatinib resistant cells. VPA was able to modify profoundly acetylome and phosphoproteome of CML cells, while reverting resistance to imatinib.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21382639 DOI： 10.1016/j.leukres.2011.01.033
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156